Skip to main content

Prostate cancer

Prostate cancer

24-09-2021 | Oncology | News | Article

Combining LuPSMA with pembrolizumab ‘promising’ for mCRPC

Results of the PRINCE trial point to the potential of LuPSMA plus pembrolizumab for the treatment of metastatic castration-resistant prostate cancer with high expression of PSMA.

20-09-2021 | Oncology | News | Article

STAMPEDE heralds ‘practice change’ for high-risk nonmetastatic prostate cancer

Supplementing androgen deprivation therapy with 2 years of an abiraterone acetate-based regimen significantly boosts the survival of men with high-risk nonmetastatic prostate cancer, show STAMPEDE results.

20-09-2021 | Oncology | News | Article

PEACE-1: Upfront triplet therapy gives OS advantage to men with mCSPC

The addition of abiraterone acetate to standard therapy with docetaxel plus androgen deprivation therapy significantly improves the overall survival of patients with de novo metastatic castration-sensitive prostate cancer, report the PEACE-1 investigators.

19-09-2021 | Oncology | News | Article

ARCHES reports enzalutamide OS benefit in men with mCSPC

The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.

08-09-2021 | Oncology | News | Article

PRONOUCE fails to resolve CV safety questions for GnRH antagonists, agonists

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

06-09-2021 | Oncology | News | Article

Significant declines in cancer diagnoses during first year of COVID-19 pandemic

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

31-08-2021 | Oncology | News | Article

Antitumor activity of talazoparib demonstrated in pretreated mCRPC

Phase 2 study data show that the PARP inhibitor talazoparib has antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer bearing DNA damage response alterations in genes associated with homologous recombination repair.

25-08-2021 | Oncology | News | Article

ERASE trial demonstrates beneficial effects of HIIT in men with prostate cancer

Men with localized prostate cancer undergoing active surveillance who follow a high-intensity interval training regimen can expect improvements in cardiorespiratory fitness and indicators of biochemical progression, early findings indicate.

18-08-2021 | Oncology | News | Article

Novel blood-based algorithm outperforms PSA for prostate cancer screening

The Stockholm3 risk prediction tool performs at least as well as prostate-specific antigen screening for the detection of clinically significant prostate cancer, research suggests.

13-08-2021 | Oncology | News | Article

Active surveillance ‘an appropriate option’ for some African–American prostate cancer patients

A US study has found no significant difference in outcomes between African–American and White men undergoing active surveillance for intermediate-risk prostate cancer.

11-08-2021 | Oncology | News | Article

Adding bone resorption inhibitors to abiraterone may prolong mCRPC survival

The addition of bone resorption inhibitors to abiraterone acetate plus prednisone is associated with improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases, especially if they have high-volume disease, researchers report.

02-08-2021 | Oncology | News | Article

Second-generation androgen receptor inhibitors supported for older nonmetastatic CRPC patients

Nonmetastatic castration-resistant prostate cancer patients aged 80 years and older benefit from treatment with second-generation androgen receptor inhibitors, suggests a pooled analysis of three trials.

26-07-2021 | Oncology | News | Article

Care of Black prostate cancer patients disproportionately affected during COVID-19

Black men with nonmetastatic prostate cancer were significantly less likely than their White counterparts to undergo prostatectomy during the initial wave of the COVID-19 pandemic, reports a US research team.

14-07-2021 | Oncology | News | Article

MRI-based biopsy approach supported for prostate cancer screening

A population-based, screening-by-invitation trial has demonstrated that a combined MRI-guided plus standard biopsy approach is noninferior to standard biopsy with regard to the detection of clinically significant prostate cancer in men with increased prostate-specific antigen levels.

07-07-2021 | Oncology | News | Article

mCRPC treatment not linked to cognitive decline

Common treatments for metastatic castration-resistant prostate cancer are not associated with significant cognitive decline in older men, research suggests.

10-06-2021 | Oncology | News | Article

Bone protecting agents a must for mCRPC patients with bone metastases

Updated safety data from the EORTC 1333/PEACE-3 trial show a marked reduction in the risk for fractures with the use of bone protecting agents in men with metastatic castration-resistant prostate cancer and bone metastases.

05-06-2021 | Oncology | News | Article

Regular PSA screening benefits young African–American men

Regular prostate cancer screening in young African–American men significantly reduces the likelihood of metastatic disease at the time of diagnosis, show study findings reported at the 2021 ASCO Annual Meeting.

05-06-2021 | Oncology | News | Article

COMBAT-CRPC points to potential of combining BAT, nivolumab

The combination of bipolar androgen therapy and nivolumab elicits responses and is well tolerated by men with metastatic castration-resistant prostate cancer, indicate phase 2 findings.

04-06-2021 | Oncology | News | Article

VISION: LuPSMA addition improves pretreated mCRPC survival

Supplementing standard of care treatment with lutetium-177-prostate-specific membrane antigen-617 significantly boosts the outcomes of heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer, say the VISION investigators.

28-05-2021 | Oncology | News | Article

Olaparib role in mCRPC ‘may need to be reconsidered’

The benefit offered by olaparib in metastatic castration-resistant prostate cancer is attenuated when a more active standard of care is used as the comparator, suggests a network analysis of the PROfound and CARD trials.

Image Credits